Cancer drug developer seeks $7b in secondary Hong Kong listing

BeiGene is offering 65.6 million shares at $94.9 to $111.6 apiece.

Bloomberg reports that cancer drug developer BeiGene Ltd., is eyeing to raise as much as $7b (US$933m) in a secondary Hong Kong listing after making its debut in New York two years earlier.

Also read: US biotech firms seeking larger valuations rush to Hong Kong

The biotech firm is offering a total of 65.6 million shares priced at $94.9 to $111.6 apiece with Baker Bros Advisors, Hillhouse Capital Management, GIC Private Ltd. and Ally Bridge agreeing to buy 19.8 million shares as cornerstone investors.

Also read: Goldman, Citi bankers abandon posts to cash in on biotech hype

Proceeds from the share sale will go into research and commercialisation of three developing drugs and expansion of the company’s portfolio and general working capital, according to a prospectus filed by the company.

At least 16 biotech firms are lining up to pursue IPOs in Hong Kong following sweeping market reforms allowing biotech firms with no track record of profitability to list.

Here’s more from Bloomberg:

Also Read

2024 Policy Address: HK expands investment scheme to include residential property assets

Hang Seng indexes to include Alibaba-W

Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

I want to download the media kit